AstraZeneca and POZEN File Patent Infringement Lawsuit Against Dr. Reddy's

POZEN Inc. POZN today announced that it and AstraZeneca filed a lawsuit against Dr. Reddy's Laboratories in the United States District Court for the District of New Jersey, for infringement of U.S. Patent No. 6,926,907 relating to VIMOVO delayed-release tablets. In a Notice Letter sent to AstraZeneca and POZEN in March 2011, Dr. Reddy's informed AstraZeneca and POZEN that it submitted an Abbreviated New Drug Application seeking U.S. Food and Drug Administration approval to market a generic version of VIMOVO prior to expiration of U.S. Patent No. 6,926,907, which is one of seven patents listed in the FDA's Orange Book for VIMOVO. The patent expires in 2023. Under the terms of its agreement with POZEN, AstraZeneca has exercised its first right to defend the patent at issue and will take the leading role in prosecuting the infringement suit against Dr. Reddy's.